Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13556407 | 0.84 | ALDH1A1 (0.58) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL2264852 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL6500450 | 0.83 | HPGD (0.63) | ALDH1A1TSHRHPGDGAAHTT | |
| SCHEMBL12961919 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| Hydrochloric Acid SCHEMBL2267196 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL2267394 | 0.82 | MAPT (0.52) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL16840366 | 0.82 | TAS1R3 (0.58) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL2270264 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL16840300 | 0.80 | HPGD (0.69) | ALDH1A1TSHRNPSR1TAS1R3TAS1R1 | |
| SCHEMBL1082046 | 0.80 | MAPK8 (0.50) | ALDH1A1TSHRGAAPKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091920-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| EP-2448924-B1 | Pyrazole derivatives, their preparation and therapeutical use | SANOFI SA (FR) | 2013-09-04 | — | — | EP | disclosed |
| US-8420824-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410286-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2013-04-02 | — | — | US | disclosed |
| US-8367715-B2 | Pyrazole derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120270918-A1 | Pyrazole Derivatives, Preparation Thereof, and Therapeutic Use Thereof | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | disclosed |
| WO-2011001122-A2 | PYRAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | disclosed |
| EP-2091920-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | Sanofi-Aventis (FR) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008065282-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2008-06-05 | — | — | WO | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | ALDH1A1 354/4885TSHR 1151/4885NPSR1 1766/4885 |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ALDH1A1 846/4885TSHR 1759/4885NPSR1 1447/4885 |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | CYP4B1, ADORA1, CYP1B1 | ALDH1A1 242/4885TSHR 1296/4885NPSR1 1834/4885 |
| US-20120270918-A1 | Pyrazole Derivatives, Preparation Thereof, and Therapeutic Use Thereof | CYP2F1, CYP4F3, CYP4F2 | ALDH1A1 410/4885TSHR 805/4885NPSR1 2754/4885 |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | ALDH1A1 354/4885TSHR 1151/4885NPSR1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.